Licensing status

Publication and contact information

Infectious disease


Pseudomonas aeruginosa pyoverdine

Mouse and in vitro studies suggest the antifungal drug flucytosine could be useful for treating P. aeruginosa infection. A screen for marketed drugs that inhibit the production of P. aeruginosa pyoverdine, a known virulence factor, identified flucytosine as one of the top hits. In P. aeruginosa clinical isolates, flucytosine inhibited pyoverdine production with micromolar to submicromolar IC50 values. In mice, prophylactic flucytosine protected all mice from a lethal P. aeruginosa challenge, whereas saline did not. Next steps include developing an inhalable formulation of flucytosine and planning a Phase I trial in patients with cystic fibrosis, who are highly susceptible to P. aeruginosa infections.
Flucytosine is a generic antifungal.

SciBX 6(15); doi:10.1038/scibx.2013.367
Published online April 18, 2013

Patent application filed covering use of flucytosine against
P. aeruginosa infections; available for licensing from Roma Tre University

Imperi, F. et al. Proc. Natl. Acad. Sci. USA; published online April 8, 2013;
Contact: Paolo Visca, Roma Tre University, Rome, Italy
Contact: Francesco Imperi, Sapienza University of Rome, Rome, Italy